» Articles » PMID: 32816871

Increasing Metformin Concentrations and Its Excretion in Both Rat and Porcine Ex Vivo Normothermic Kidney Perfusion Model

Abstract

Introduction: Metformin can accumulate and cause lactic acidosis in patients with renal insufficiency. Metformin is known to inhibit mitochondria, while renal secretion of the drug by proximal tubules indirectly requires energy. We investigated whether addition of metformin before or during ex vivo isolated normothermic machine perfusion (NMP) of porcine and rat kidneys affects its elimination.

Research Design And Methods: First, Lewis rats were pretreated with metformin or saline the day before nephrectomy. Subsequently, NMP of the kidney was performed for 90 min. Metformin was added to the perfusion fluid in one of three different concentrations (none, 30 mg/L or 300 mg/L). Second, metformin was added in increasing doses to the perfusion fluid during 4 hours of NMP of porcine kidneys. Metformin concentration was determined in the perfusion fluid and urine by liquid chromatography-tandem mass spectrometry.

Results: Metformin clearance was approximately 4-5 times higher than creatinine clearance in both models, underscoring secretion of the drug. Metformin clearance at the end of NMP in rat kidneys perfused with 30 mg/L was lower than in metformin pretreated rats without the addition of metformin during perfusion (both p≤0.05), but kidneys perfused with 300 mg/L trended toward lower metformin clearance (p=0.06). Creatinine clearance was not different between treatment groups. During NMP of porcine kidneys, metformin clearance peaked at 90 min of NMP (18.2±13.7 mL/min/100 g). Thereafter, metformin clearance declined, while creatinine clearance remained stable. This observation can be explained by saturation of metformin transporters with a Michaelis-Menten constant (95% CI) of 23.0 (10.0 to 52.3) mg/L.

Conclusions: Metformin was secreted during NMP of both rat and porcine kidneys. Excretion of metformin decreased under increasing concentrations of metformin, which might be explained by saturation of metformin transporters rather than a self-inhibitory effect. It remains unknown whether a self-inhibitory effect contributes to metformin accumulation in humans with longer exposure times.

Citing Articles

Research Methods and New Advances in Drug-Drug Interactions Mediated by Renal Transporters.

Lin K, Kong X, Tao X, Zhai X, Lv L, Dong D Molecules. 2023; 28(13).

PMID: 37446913 PMC: 10343503. DOI: 10.3390/molecules28135252.


The development and benefits of metformin in various diseases.

Dong Y, Qi Y, Jiang H, Mi T, Zhang Y, Peng C Front Med. 2023; 17(3):388-431.

PMID: 37402952 DOI: 10.1007/s11684-023-0998-6.


Doxycycline Alters the Porcine Renal Proteome and Degradome during Hypothermic Machine Perfusion.

van Leeuwen L, Venema L, Heilig R, Leuvenink H, Kessler B Curr Issues Mol Biol. 2022; 44(2):559-577.

PMID: 35723325 PMC: 8928973. DOI: 10.3390/cimb44020039.

References
1.
Qi H, Nielsen P, Schroeder M, Bertelsen L, Palm F, Laustsen C . Acute renal metabolic effect of metformin assessed with hyperpolarised MRI in rats. Diabetologia. 2017; 61(2):445-454. DOI: 10.1007/s00125-017-4445-6. View

2.
Li J, Gui Y, Ren J, Liu X, Feng Y, Zeng Z . Metformin Protects Against Cisplatin-Induced Tubular Cell Apoptosis and Acute Kidney Injury via AMPKα-regulated Autophagy Induction. Sci Rep. 2016; 6:23975. PMC: 4823749. DOI: 10.1038/srep23975. View

3.
Chatauret N, Thuillier R, Hauet T . Preservation strategies to reduce ischemic injury in kidney transplantation: pharmacological and genetic approaches. Curr Opin Organ Transplant. 2011; 16(2):180-7. DOI: 10.1097/MOT.0b013e3283446b1d. View

4.
Cucchiari D, Podesta M, Merizzoli E, Calvetta A, Morenghi E, Angelini C . Dose-related effects of metformin on acid-base balance and renal function in patients with diabetes who develop acute renal failure: a cross-sectional study. Acta Diabetol. 2016; 53(4):551-8. DOI: 10.1007/s00592-016-0836-2. View

5.
Posma R, Lexis C, Lipsic E, Nijsten M, Damman K, Touw D . Effect of Metformin on Renal Function After Primary Percutaneous Coronary Intervention in Patients Without Diabetes Presenting with ST-elevation Myocardial Infarction: Data from the GIPS-III Trial. Cardiovasc Drugs Ther. 2016; 29(5):451-9. PMC: 4636992. DOI: 10.1007/s10557-015-6618-1. View